Real-world data highlights Lybalvi’s impact on acute care use in high-risk patients and Aristada’s long-acting dosing for steadier schizophrenia treatment.
Hemangi Panchmatia, MS
Advertisement
Articles by Hemangi Panchmatia, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
2
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
The Psychiatric Pipeline in Review: Quarter 3, 2026
5